Bayer's AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure (CHF)

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, have announced the initiation of GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002 (also known as NAN-101) for the treatment of congestive heart failure (CHF).

from Breaking World Pharma News https://ift.tt/Zd7vlpV